Goodwin GM

Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder.

Dougherty RF, Modlin NL, McGowan NM +11

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.

Goodwin GM, Aaronson ST, Alvarez O +23

The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience: A Retrospective Analysis.

Kirlić N, Atli M, Mistry S +2

Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment.

Modlin NL, Williamson V, Goodwin GM +10

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].

Goodwin GM, Aaronson ST, Alvarez O +28

Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial.

McGowan NM, Rucker JJ, Yehuda R +6

Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions.

Kirlić N, Lennard-Jones M, Atli M +6

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.

Goodwin GM, Aaronson ST, Alvarez O +28

The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression.

Marwood L, Croal M, Mistry S +4

ArticlePsychedelics

Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?

Pasculli G, Busan P, Jackson ES +7

Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects.

E-Wen McCulloch D, Liechti ME, Kuypers KP +9

Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary.

Goodwin GM, Malievskaia E, Fonzo GA +1

ArticlePsychedelics

The psychedelic experience and treatment-resistant depression.

Goodwin GM

Europe PMC2023

Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing.

Dougherty RF, Clarke P, Atli M +10

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.

Goodwin GM, Croal M, Feifel D +11

Europe PMC2023

Unblinding and demand characteristics in the treatment of depression.

Goodwin GM, Croal M, Marwood L +1

Europe PMC2023

Psilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice.

Thomas CW, Blanco-Duque C, Bréant BJ +4

Europe PMC2022

PreprintPsilocybin

Psilocin acutely disrupts sleep and affects local but not global sleep homeostasis in laboratory mice

Thomas CW, Blanco-Duque C, Bréant B +4

Europe PMC2021